Media Advisory/Photo Opportunity - CNIB unleashes the power of technology to mark Global Accessibility Awareness Day
TORONTO, May 16, 2018 /CNW/ - To mark Global Accessibility Awareness Day, CNIB is announcing a bold ambition: to unleash the power of technology across Canada and make the country more inclusive and accessible in the process.
Join CNIB on May 17, 2018 at the CNIB Community Hub for a special technology partnership announcement with Aira, BlindSquare and Key2Access.
The event will include hands-on demonstrations of of Aira, BlindSquare and Key2Access for clients and attendees.
Len Baker - Vice-President, Partnerships and Innovation, CNIB
Kevin Phelan ? Vice President, Aira
Sophie Aladas ? CEO, Key2Access
CNIB Clients
About CNIB Celebrating 100 years in 2018, CNIB is a non-profit organization driven to change what it is to be blind today. We deliver innovative programs and powerful advocacy that empower people impacted by blindness to live their dreams while tearing down barriers to inclusion. Our work is powered by a network of volunteers, donors and partners from coast to coast to coast. To learn more or get involved, visit cnib.ca.
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
